[Form 4] Generation Bio Co. Insider Trading Activity

Rhea-AI Filing Summary

Generation Bio (GBIO) reported an insider transaction by its Chief Financial Officer on 10/15/2025. The filing shows 58 shares of common stock were acquired following the settlement of restricted stock units (Code M), and 18 shares were disposed of at $6.71 (Code F). Following these transactions, the officer directly owned 1,867 shares.

The report notes a one-for-10 reverse stock split effected on July 21, 2025. It also references a grant of 939 restricted stock units made on January 20, 2023, with 25% vested on January 15, 2024, and the remainder vesting in equal quarterly installments thereafter.

Insider Trade Summary

58 shares exercised/converted

Mixed 3 txns

Insider Conway Kevin John

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	58	$0.00	--
Exercise	Common Stock	58	$0.00	--
Tax Withholding	Common Stock	18	$6.71	$120.78

Holdings After Transaction: Restricted Stock Units — 294 shares (Direct); Common Stock — 1,885 shares (Direct)

Footnotes (1)

1. Amounts reported in this Form 4 reflect the one-for-10 reverse stock split effected by the issuer on July 21, 2025. Each restricted stock unit represents the right to receive one share of the company's common stock. The grant of 939 restricted stock units was made on January 20, 2023. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Conway Kevin John

(Last) (First) (Middle)

C/O GENERATION BIO CO.

301 BINNEY ST, SUITE 401

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generation Bio Co. [ GBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		M		58(1)	A	(2)	1,885(1)	D
Common Stock	10/15/2025		F		18(1)	D	$6.71	1,867(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	10/15/2025		M			58(1)	(3)	(3)	Common Stock	58(1)	$0	294(1)	D

Explanation of Responses:

1. Amounts reported in this Form 4 reflect the one-for-10 reverse stock split effected by the issuer on July 21, 2025.

2. Each restricted stock unit represents the right to receive one share of the company's common stock.

3. The grant of 939 restricted stock units was made on January 20, 2023. The shares underlying the restricted stock units vest over four years, with 25% of the shares vested on January 15, 2024 and the remaining shares vesting in equal quarterly installments thereafter.

	/s/ Shawna-Gay White, Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.